Using the largest Asian LUAD patient dataset as a starting point, we have identified PARP4 copy number loss or mutation at relatively high frequency, which we subsequently validated in vitro and in vivo as an important modulator of tumor progression. This evidence concerns the gene PARP4 and neoplasm.